Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis Go to source) shows that a combination of Transcutaneous Spinal Cord Stimulation (TSS ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

Spinal cord and dorsal root ganglion stimulation ... causes of explantation associated with different SCS and DRG stimulation devices. Differences between manufacturers in 5-year explantation ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Spinal cord and dorsal root ganglion stimulation are established ... They sought to assess 5- and 10-year explantation risks and examine causes of explantation associated with different SCS and DRG ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud ...

Nevro Corp. NVRO recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system. The ...